Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(9):1163–1169. doi: 10.1038/bjc.1997.528

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

W C Vooijs 1, H G Otten 1, M van Vliet 1, A J van Dijk 1, R A de Weger 1, M de Boer 1, H Bohlen 1, A Bolognesi 1, L Polito 1, G C de Gast 1
PMCID: PMC2228107  PMID: 9365164

Abstract

In this preclinical study, the potential applicability of an anti-B7-1 immunotoxin (IT) for the treatment of Hodgkin's disease (HD) was investigated. Immunohistochemical analysis demonstrated strong expression of B7-1 on Hodgkin and Reed-Sternberg (R-S) cells and clear expression on dendritic cells, macrophages and some B-cells in tissues, but not on other tissue cells. Flow cytometric analysis demonstrated that B7-1 was expressed on a few monocytes, but not on CD34+ cells from bone marrow, resting T- or B-cells from peripheral blood or epithelial and endothelial cell lines. An anti-B7-1 immunotoxin containing the anti-B7-1 monoclonal antibody (MAb) B7-24 and saporin as toxin moiety was constructed and showed an affinity similar to that shown by the native MAb. It exhibited strong cytotoxicity against the B7-1+ B-cell line Raji (IC50 10(-11) M), R-S cell lines HDLM2, KM/H2 and L428 and also against a B7-1-transfected epithelial cell line, A431, whose parental line lacks expression of B7-1. In clonogenic assays with Raji cells or KM/H2 cells, a 3- or 4-log kill, respectively, was observed. No cytotoxicity was found against the B7-1- epithelial and endothelial cell lines or against haematopoietic progenitor cells. In conclusion, an anti-B7-1 immunotoxin was developed that had good cytotoxicity against R-S cell lines and that may be used in the elimination of R-S cells in vivo. A concomitant elimination of activated antigen-presenting cells may avoid development of antitoxin and anti-mouse Ig responses and allow repeated administration.

Full text

PDF
1163

Images in this article

1164Figure 1
on p.1164

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azuma M., Cayabyab M., Buck D., Phillips J. H., Lanier L. L. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med. 1992 Feb 1;175(2):353–360. doi: 10.1084/jem.175.2.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azuma M., Cayabyab M., Phillips J. H., Lanier L. L. Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol. 1993 Mar 15;150(6):2091–2101. [PubMed] [Google Scholar]
  3. Bast R. C., Jr, De Fabritiis P., Lipton J., Gelber R., Maver C., Nadler L., Sallan S., Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb;45(2):499–503. [PubMed] [Google Scholar]
  4. Caux C., Vanbervliet B., Massacrier C., Azuma M., Okumura K., Lanier L. L., Banchereau J. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med. 1994 Nov 1;180(5):1841–1847. doi: 10.1084/jem.180.5.1841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chelen C. J., Fang Y., Freeman G. J., Secrist H., Marshall J. D., Hwang P. T., Frankel L. R., DeKruyff R. H., Umetsu D. T. Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. J Clin Invest. 1995 Mar;95(3):1415–1421. doi: 10.1172/JCI117796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DeVita V. T., Jr, Hubbard S. M. Hodgkin's disease. N Engl J Med. 1993 Feb 25;328(8):560–565. doi: 10.1056/NEJM199302253280808. [DOI] [PubMed] [Google Scholar]
  7. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992 Feb 7;68(3):421–427. doi: 10.1016/0092-8674(92)90180-k. [DOI] [PubMed] [Google Scholar]
  8. Engert A., Martin G., Pfreundschuh M., Amlot P., Hsu S. M., Diehl V., Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice. Cancer Res. 1990 May 15;50(10):2929–2935. [PubMed] [Google Scholar]
  9. Falini B., Flenghi L., Fedeli L., Broe M. K., Bonino C., Stein H., Dürkop H., Bigerna B., Barbabietola G., Venturi S. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol. 1992 Sep;82(1):38–45. doi: 10.1111/j.1365-2141.1992.tb04591.x. [DOI] [PubMed] [Google Scholar]
  10. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., Martelli M. F., Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85(1):1–14. [PubMed] [Google Scholar]
  11. Freeman G. J., Freedman A. S., Segil J. M., Lee G., Whitman J. F., Nadler L. M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 1989 Oct 15;143(8):2714–2722. [PubMed] [Google Scholar]
  12. Gause A., Pohl C., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever D., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood. 1991 May 1;77(9):1983–1988. [PubMed] [Google Scholar]
  13. Gruss H. J., Hirschstein D., Wright B., Ulrich D., Caligiuri M. A., Barcos M., Strockbine L., Armitage R. J., Dower S. K. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood. 1994 Oct 1;84(7):2305–2314. [PubMed] [Google Scholar]
  14. Guinan E. C., Gribben J. G., Boussiotis V. A., Freeman G. J., Nadler L. M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15;84(10):3261–3282. [PubMed] [Google Scholar]
  15. Haagen I. A., Geerars A. J., de Lau W. B., Bast B. J., de Gast B. C. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood. 1995 Jun 1;85(11):3208–3212. [PubMed] [Google Scholar]
  16. Haluska F. G., Brufsky A. M., Canellos G. P. The cellular biology of the Reed-Sternberg cell. Blood. 1994 Aug 15;84(4):1005–1019. [PubMed] [Google Scholar]
  17. Hertler A. A., Spitler L. E., Frankel A. E. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Deliv. 1987;4(4):245–253. doi: 10.1089/cdd.1987.4.245. [DOI] [PubMed] [Google Scholar]
  18. Josimovic-Alasevic O., Dürkop H., Schwarting R., Backé E., Stein H., Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol. 1989 Jan;19(1):157–162. doi: 10.1002/eji.1830190125. [DOI] [PubMed] [Google Scholar]
  19. Larsen C. P., Ritchie S. C., Hendrix R., Linsley P. S., Hathcock K. S., Hodes R. J., Lowry R. P., Pearson T. C. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol. 1994 Jun 1;152(11):5208–5219. [PubMed] [Google Scholar]
  20. McLellan A. D., Starling G. C., Williams L. A., Hock B. D., Hart D. N. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. Eur J Immunol. 1995 Jul;25(7):2064–2068. doi: 10.1002/eji.1830250739. [DOI] [PubMed] [Google Scholar]
  21. Munro J. M., Freedman A. S., Aster J. C., Gribben J. G., Lee N. C., Rhynhart K. K., Banchereau J., Nadler L. M. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 1994 Feb 1;83(3):793–798. [PubMed] [Google Scholar]
  22. Nozawa Y., Wachi E., Tominaga K., Abe M., Wakasa H. A novel monoclonal antibody (FUN-1) identifies an activation antigen in cells of the B-cell lineage and Reed-Sternberg cells. J Pathol. 1993 Mar;169(3):309–315. doi: 10.1002/path.1711690306. [DOI] [PubMed] [Google Scholar]
  23. Pai L. H., Bookman M. A., Ozols R. F., Young R. C., Smith J. W., 2nd, Longo D. L., Gould B., Frankel A., McClay E. F., Howell S. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol. 1991 Dec;9(12):2095–2103. doi: 10.1200/JCO.1991.9.12.2095. [DOI] [PubMed] [Google Scholar]
  24. Parente A., De Luca P., Bolognesi A., Barbieri L., Battelli M. G., Abbondanza A., Sande M. J., Gigliano G. S., Tazzari P. L., Stirpe F. Purification and partial characterization of single-chain ribosome-inactivating proteins from the seeds of Phytolacca dioica L. Biochim Biophys Acta. 1993 Oct 19;1216(1):43–49. doi: 10.1016/0167-4781(93)90035-c. [DOI] [PubMed] [Google Scholar]
  25. Pasqualucci L., Wasik M., Teicher B. A., Flenghi L., Bolognesi A., Stirpe F., Polito L., Falini B., Kadin M. E. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995 Apr 15;85(8):2139–2146. [PubMed] [Google Scholar]
  26. Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T., Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br J Haematol. 1990 Jun;75(2):282–284. doi: 10.1111/j.1365-2141.1990.tb02664.x. [DOI] [PubMed] [Google Scholar]
  27. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol. 1989 Aug;135(2):351–357. [PMC free article] [PubMed] [Google Scholar]
  28. Post J., Vooys W. C., de Gast G. C., Bast B. J. Comparison of various in vitro assays for efficacy screening of immunotoxins. Leuk Res. 1995 Apr;19(4):241–247. doi: 10.1016/0145-2126(94)00142-w. [DOI] [PubMed] [Google Scholar]
  29. Schwarting R., Gerdes J., Dürkop H., Falini B., Pileri S., Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989 Oct;74(5):1678–1689. [PubMed] [Google Scholar]
  30. Smith C. A., Gruss H. J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G. R., Brannan C. I., Copeland N. G., Jenkins N. A. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell. 1993 Jul 2;73(7):1349–1360. doi: 10.1016/0092-8674(93)90361-s. [DOI] [PubMed] [Google Scholar]
  31. Symington F. W., Brady W., Linsley P. S. Expression and function of B7 on human epidermal Langerhans cells. J Immunol. 1993 Feb 15;150(4):1286–1295. [PubMed] [Google Scholar]
  32. Tazzari P. L., Bolognesi A., de Totero D., Falini B., Lemoli R. M., Soria M. R., Pileri S., Gobbi M., Stein H., Flenghi L. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol. 1992 Jun;81(2):203–211. doi: 10.1111/j.1365-2141.1992.tb08208.x. [DOI] [PubMed] [Google Scholar]
  33. Vandenberghe P., Delabie J., de Boer M., De Wolf-Peeters C., Ceuppens J. L. In situ expression of B7/BB1 on antigen-presenting cells and activated B cells: an immunohistochemical study. Int Immunol. 1993 Mar;5(3):317–321. doi: 10.1093/intimm/5.3.317. [DOI] [PubMed] [Google Scholar]
  34. Vooijs W. C., Post J., Wijdenes J., Schuurman H. J., Bolognesi A., Polito L., Stirpe F., Bast E. J., de Gast G. C. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother. 1996 Jul;42(6):319–328. doi: 10.1007/s002620050289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Vriesendorp H. M., Herpst J. M., Germack M. A., Klein J. L., Leichner P. K., Loudenslager D. M., Order S. E. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol. 1991 Jun;9(6):918–928. doi: 10.1200/JCO.1991.9.6.918. [DOI] [PubMed] [Google Scholar]
  36. Young J. W., Koulova L., Soergel S. A., Clark E. A., Steinman R. M., Dupont B. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest. 1992 Jul;90(1):229–237. doi: 10.1172/JCI115840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Zhou L. J., Tedder T. F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995 Apr 15;154(8):3821–3835. [PubMed] [Google Scholar]
  38. de Boer M., Parren P., Dove J., Ossendorp F., van der Horst G., Reeder J. Functional characterization of a novel anti-B7 monoclonal antibody. Eur J Immunol. 1992 Dec;22(12):3071–3075. doi: 10.1002/eji.1830221207. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES